Il-6

1 trends tracked about this subject — the full history, oldest to newest below.

◼ Archived Business 🔮 fades ✓

Novo Nordisk has terminated two additional phase 3 trials of its cardiovascular drug ziltivekimab due to futility, impacting its growth strategy.

5 sources 5 articles v 3 46d ago

\n \n \n

\n \n \n \n